Clinical Trials
73 trialsNCT07092410 2026-04-21
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Phase 4 Withdrawn
NCT04129515 2026-01-02
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Brown University
Phase 1/2 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT01861938 2025-10-02
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Hadassah Medical Organization
Phase 2/3 Withdrawn
NCT05717140 2025-08-07
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Mayo Clinic
Phase 1 Withdrawn
NCT06508827 2025-07-09
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Indiana University
Phase 2 Withdrawn
NCT04099446 2025-06-05
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
ProgenaBiome
Withdrawn
NCT06190249 2025-06-05
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02145910 2025-05-02
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Thomas Jefferson University
Phase 1 Withdrawn
NCT03448666 2024-09-23
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
European Institute of Oncology
Phase 2 Withdrawn
NCT03989050 2024-09-20
SPICE
University of Cologne
Withdrawn
NCT05482074 2024-01-19
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT00979693 2023-12-26
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
Multidisciplinary Association for Psychedelic Studies
Phase 2 Withdrawn
NCT02143050 2023-11-18
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
Phase 1/2 Withdrawn
NCT05299580 2023-09-14
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
Phase 2 Withdrawn
NCT04987996 2023-06-06
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
Phase 2 Withdrawn
NCT04703426 2023-05-22
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04941365 2022-12-22
SERPENTINE
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Withdrawn
NCT03754140 2022-07-14
INTRANS
Melanoma Institute Australia
Phase 2 Withdrawn
NCT04223648 2021-11-22
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Yale University
Phase EARLY_PHASE1 Withdrawn
NCT04042506 2021-04-12
SBRT as a Vaccination for Metastatic Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT03758729 2021-02-16
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Samsung Medical Center
Phase 2 Withdrawn
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT03126461 2020-08-20
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT01826864 2020-07-27
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Jonsson Comprehensive Cancer Center
Phase 3 Withdrawn
NCT02263898 2020-07-27
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04285749 2020-07-27
Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT01355562 2020-04-30
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
Phase 2 Withdrawn
NCT04125719 2020-02-11
PPD1
Duke University
Phase 1 Withdrawn
NCT02828345 2020-02-05
Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma
Abramson Cancer Center at Penn Medicine
Withdrawn
NCT04007588 2020-02-05
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT03982134 2019-10-04
PDR001 + Panobinostat for Melanoma and NSCLC
University of Iowa
Phase 1 Withdrawn
NCT03111901 2019-07-12
UVA-AM-002
University of Virginia
Phase 1/2 Withdrawn
NCT02300935 2019-05-30
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
SCRI Development Innovations, LLC
Phase 1 Withdrawn
NCT03518229 2019-04-17
Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors
University of Minnesota
Phase NA Withdrawn
NCT02068079 2019-01-30
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Duke University
Phase 1 Withdrawn
NCT03177941 2018-11-16
Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology
Northwestern University
Phase NA Withdrawn
NCT03297463 2018-08-01
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT00406120 2018-06-26
Validation of a Molecular Prognostic Test for Eye Melanoma
Washington University School of Medicine
Withdrawn
NCT02915666 2018-05-15
A Clinical Trial of Patients With Melanoma
University of Texas Southwestern Medical Center
Phase 1 Withdrawn
NCT03282188 2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2 Withdrawn
NCT02812693 2018-04-05
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Ohio State University Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00588263 2018-02-19
Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer
Memorial Sloan Kettering Cancer Center
Withdrawn
NCT00769990 2017-12-13
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT02719015 2017-11-24
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02736123 2017-09-20
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
University of Pittsburgh
Phase 1/2 Withdrawn
NCT01833767 2017-08-24
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Western Regional Medical Center
Phase 2 Withdrawn
NCT02210104 2017-07-21
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01843738 2017-05-24
Radiation Use During Vemurafenib Treatment
University of Utah
Phase 1 Withdrawn
NCT02400385 2017-02-01
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
California Pacific Medical Center Research Institute
Phase 2 Withdrawn